Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5/10/24 19:00 | 5/8/24 | MRNA | Health | BioPrd | Biological Products, (No Diag | Afeyan Noubar | MA | D | 38 | S | -63,667 | 122.44 | 0 | -520 | 15,154 | D | ||||||||||||||||
4/16/24 16:23 | 4/15/24 | MRNA | Health | BioPrd | Biological Products, (No Diag | Hoge Stephen | MA | O | P | 25 | S.d | -19,687 | 105.74 | 0 | -186 | 1,788 | D | |||||||||||||||
4/9/24 16:09 | 4/8/24 | MRNA | Health | BioPrd | Biological Products, (No Diag | Mock James M | MA | O | CFO | 4 | S.d | -511 | 102.52 | 0 | -5 | 5 | D | |||||||||||||||
3/11/24 09:05 | 3/8/24 | MRNA | Health | BioPrd | Biological Products, (No Diag | Klinger Shannon Thyme | MA | O | GC | 11 | S.d | -481 | 109.93 | 0 | -4 | 9 | D | |||||||||||||||
2/16/24 16:10 | 2/16/24 | MRNA | Health | BioPrd | Biological Products, (No Diag | Bancel Stephane | MA | DO | CEO | 28 | S.dm | -321,116 | 149.81 | 0 | -2,144 | 21,075 | D | |||||||||||||||
12/7/23 16:21 | 12/6/23 | MRNA | Health | BioPrd | Biological Products, (No Diag | Garay Arpa | MA | O | Chief Co | 3 | S.d | -394 | 115.04 | 0 | -3 | 4 | D | |||||||||||||||
12/30/22 16:31 | 12/28/22 | MRNA | Health | BioPrd | Biological Products, (No Diag | Andres Juan | MA | O | See rema | 1 | S.d | -360 | 180.00 | 0 | -2 | 13 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |